Indivior is still primarily an opioid-use-disorder company built around SUBLOCADE, while the announced Supernus combination is meant to broaden it into a scaled CNS portfolio; the proposed merger was already framed around roughly $2.2 billion of combined revenue and $125 million of annual cost synergies.
This formalizes, rather than changes, the merger economics. The board declared an $8.13-per-share special dividend, with the same amount applying to certain equity awards. The merger agreement had already disclosed that a special dividend would be paid to Indivior holders, so the key new information is the precise per-share amount and timetable—not a new strategic decision.
The dividend remains a closing-dependent benefit, not cash in hand today. Payment is explicitly contingent on completing the Supernus merger, and Indivior says it will not pay the dividend if the transaction fails. 〔0〕 Assuming a November 2 closing, payment is expected around November 6, after the October 30 record date. 〔1〕
The business story is largely unchanged, with financing and execution risk still attached to the merger. The filing itself flags the additional indebtedness used to fund the dividend and the possibility that the transaction does not close or that expected synergies are not realized. 〔2〕 Those are existing merger risks, not newly worsened risks in this announcement.
Bottom line: This is a confirmation and specification of an already disclosed merger-linked dividend, not a fresh catalyst for Indivior’s operating story. It makes the cash-return mechanics clearer, but the payment still depends entirely on shareholder approvals and closing the Supernus deal.
Read the original 8-K on SEC EDGAR ↗